Sandoz's Enbrel biosim case turned away at SCOTUS, giving Amgen's blockbuster 8 more years of free rein

After back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up its long shot biosimilars case against Enbrel maker Amgen. But now that effort has failed, giving Amgen a clear path to many more years of blockbuster sales for its top drug.